trending Market Intelligence /marketintelligence/en/news-insights/trending/-PmEznS4sGgLJz1C-MvcfA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Adherium bags US FDA approval to sell inhaler sensor directly to consumers

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Adherium bags US FDA approval to sell inhaler sensor directly to consumers

Adherium Ltd. said the U.S. Food and Drug Administration granted the company 510(k) clearance to sell its inhaler sensor directly to consumers without a prescription.

The regulator granted over-the-counter clearance for Adherium's Smartinhaler sensor, a device intended to be installed onto AstraZeneca PLC's asthma inhaler Symbicort. The device monitors a patient's usage of the inhaler and sends that data to an app on the user's phone or tablet as part of a self-management plan.

The San Mateo, Calif.-based company develops digital health technology for chronic diseases, such as asthma and chronic obstructive pulmonary disease.